Enhancing clinical trial development for pediatric kidney diseases

H. William Schnaper, Joseph T. Flynn, Coleman Gross, Anne B. Cropp, Bastian Dehmel, Leah B. Patel, Larry A. Greenbaum, Elisabeth Houtsmuller, Frederick Kaskel, Marva Moxey-Mims, Karen Nowak, Douglas Silverstein, Aliza Thompson, Lynne Yao, Edress Darsey, William E. Smoyer

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


The conduct of clinical trials in small pediatric subspecialties such as pediatric nephrology is hampered by both clinical demands on the pediatric nephrologist and the small number of appropriate patients available for such studies. The American Society of Pediatric Nephrology Therapeutics Development Committee (TDC) was established to (1) identify the various stakeholders with interests and/or expertise related to clinical trials in children with kidney disease and (2) develop more effective partnerships among all parties regarding strategies for successful clinical trial development and execution. This article discusses the rationale, structure, and function of the TDC, the status of progress toward its goals, and the insights gained to date that may be useful for other subspecialties that face similar challenges.

Original languageEnglish (US)
Pages (from-to)727-732
Number of pages6
JournalPediatric Research
Issue number5
StatePublished - Nov 1 2017

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Enhancing clinical trial development for pediatric kidney diseases'. Together they form a unique fingerprint.

Cite this